Latest

The Analytics Revolution of 2018: Transforming Insights to Action in the Life Sciences Industry

Scott Beauchamp discussed the future of analytics in the life sciences industry—and look at how peers in other industries have reaped the benefits of being early movers.

Trump Budget Boosts FDA, Squeezes Resources for NIH & Healthcare

Advocates on all sides applauded the request to increase funding significantly for FDA under the Trump administration’s budget for fiscal year 2019.

Engaging Patients, Engaging the Public

Pharm Exec speaks to Jane Griffiths, Global Head of Actelion, about the current state of the industry's reputation and the work that needs to be done to further build trust with patients and the public.

The Chinese Pharmaceutical Industry: Winners and Losers 2017

Jin Zhang reviews the current fortunes of the Chinese pharmaceutical companies.

Industry Trends 2018

12 Life Sciences Trends to Look Forward to in 2018

By Veeva Systems

Veeva Systems highlights its top 12 trends for the life sciences industry in 2018.

Syneos Health 2018 Trends Forecast

By Syneos Health

Syneos Health released its trends forecast, identifying 15 important trends that shape stakeholder perspectives, challenge conventional launch wisdom, and drive innovation affecting every aspect of the customer experience, starting with early clinical development and beyond.

"Value" Will Define the Next Year

By Cassandra Sinclair

Wunderman Health's Cassandra Sinclair discusses how value plays a role in the shifting landscape for 2018.

PharmExec Videos

New & Noteworthy

How Tax Reform Will Affect the Pharmaceutical Industry

This article examines the key ways the new tax bill will impact the pharmaceutical industry.

The Innovation Distinction: Biopharma's Reputational Pass

The biotech sector has managed to elude the negative perceptions saddling traditional pharma these days. We examine the reasons why.

Pharma's Image Fix: Lessons from the Field

Lieutenant General (Ret) Rick Lynch, US Army, and Bob Jansen, CEO of Zensights, discuss the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader.

Accentuate the Positive: Tackling Pharma’s Reputation Problem

Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to its stakeholders—most importantly, patients and the wider public.

Sales & Marketing

Listening Is the Key to Becoming More Than Just Better Marketers

But how much better would our creative be if we took the time to really listen to what our clients are saying – and what they are not saying – rather than reading between the lines of an RFP?

Building on Awareness to Improve Brand Adoption and Conversion Rates

Vickie Andros and Jake Caines discuss how to identify and overcome barriers that keep prescriptions from getting to the pharmacy, and most importantly, to the patient.

High Risk, High Reward: Understanding, Embracing, and Aligning on Risks in Your Next Outcomes-Based Contract

Shared understanding of both risks and benefits to all parties in the healthcare continuum is essential in order to deliver more value, write Vickie Andros and Jake Caines.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

Showdown Approaching on European Research Incentives

In the coming weeks, the EU will decide if the degree of protection offered to drug firms by research incentives such as the SPC are really in the interests of patients and society. Reflector reports.

Digital Innovation: Staying Ahead of the Curve

Rather than looking at what their peers are doing in digital health, pharma companies need to anticipate new challengers in the healthcare industry, writes Kal Patel.

Data as Media: A New Opportunity for Marketers

This blog discusses the benefits of the pharma industry adopting the idea that media is data.

Leadership in All the Right Places

Drawing parallels from the world of football coaching in evaluating and grooming future C-suite pharma leaders—call it the quest to see "what right looks like?"

Compliance Top of Mind

There is never a lack of legal or regulatory issues to keep track of—and worry about—in the life sciences industry. The articles from Pharmaceutical Executive provide a look at the latest in compliance for marketing, labeling, and export control, as well as offer tips to stay compliant in the coming years.
 

Read More.

Interviews

Engaging Patients, Engaging the Public

Pharm Exec speaks to Jane Griffiths, Global Head of Actelion, about the current state of the industry's reputation and the work that needs to be done to further build trust with patients and the public.

Valeant’s Northern Face

In this Q&A, Richard Lajoie, the new head of Valeant Canada, shares his main priorities for the business, including growing its domestic manufacturing as a key cog globally.

Q&A: From Gleevec to CAR-T

Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer and the related broader issues such as pricing and value and new innovations in cancer science.

Regulatory

Trump Budget Boosts FDA, Squeezes Resources for NIH & Healthcare

Advocates on all sides applauded the request to increase funding significantly for FDA under the Trump administration’s budget for fiscal year 2019.

Gottlieb To Promote Biosimilars, Safer Opioid Packaging

Commissioner Scott Gottlieb this week outlined FDA plans to continue the fight against opioid addiction and to prepare a “comprehensive plan” to bolster the market for biosimilars.

More New Drugs and Generics Reshape Pharma Markets

Low-cost follow-ons and biosimilars please payers but heighten competitive battles with brands.

From the Editor

Leadership in All the Right Places

Drawing parallels from the world of football coaching in evaluating and grooming future C-suite pharma leaders—call it the quest to see "what right looks like?"

CAR-T Concerns for Continued Success

The advent of immunocellular therapies marks a major milestone in medical innovation, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance.

lorem ipsum